Dermatomyositis - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dermatomyositis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Dermatomyositis - Pipeline Review, H1 2016', provides an overview of the Dermatomyositis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dermatomyositis
- The report reviews pipeline therapeutics for Dermatomyositis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Dermatomyositis therapeutics and enlists all their major and minor projects
- The report assesses Dermatomyositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Dermatomyositis


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Dermatomyositis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dermatomyositis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dermatomyositis Overview 6
Therapeutics Development 7
Pipeline Products for Dermatomyositis - Overview 7
Dermatomyositis - Therapeutics under Development by Companies 8
Dermatomyositis - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Dermatomyositis - Products under Development by Companies 11
Dermatomyositis - Companies Involved in Therapeutics Development 12
F. Hoffmann-La Roche Ltd. 12
Hope Pharmaceuticals, Inc. 13
Idera Pharmaceuticals, Inc. 14
MedImmune, LLC 15
Neovacs SA 16
Novartis AG 17
Dermatomyositis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
IMO-8400 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
JBT-101 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MEDI-7734 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
siponimod - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
sodium thiosulfate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
tocilizumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Dermatomyositis - Recent Pipeline Updates 42
Dermatomyositis - Dormant Projects 60
Dermatomyositis - Product Development Milestones 61
Featured News & Press Releases 61
Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 61
Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum 61
Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015 62
Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis 62
Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 63
Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 64
Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis 65
May 13, 2015: Neovacs granted 1.8 million euros in research tax credit 66
Aug 08, 2014: Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis 66
Mar 13, 2014: Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables

Number of Products under Development for Dermatomyositis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Dermatomyositis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 12
Dermatomyositis - Pipeline by Hope Pharmaceuticals, Inc., H1 2016 13
Dermatomyositis - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 14
Dermatomyositis - Pipeline by MedImmune, LLC, H1 2016 15
Dermatomyositis - Pipeline by Neovacs SA, H1 2016 16
Dermatomyositis - Pipeline by Novartis AG, H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Stage and Target, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Dermatomyositis Therapeutics - Recent Pipeline Updates, H1 2016 42
Dermatomyositis - Dormant Projects, H1 2016 60